Hormonal Therapy and Tirzepatide: A Promising Weight Loss Combination for Postmenopausal Women
Understanding Menopause and Weight Gain
Women going through menopause often face various symptoms, including weight gain. This weight gain can be particularly challenging to manage due to hormonal changes and a slower metabolism. Menopause typically occurs between the ages of 45 and 55, marking the end of a woman’s reproductive years. Alongside the cessation of menstrual cycles, menopause can lead to symptoms such as hot flashes, mood swings, fatigue, sleep disturbances, and an increase in weight. Research indicates that women in the perimenopausal phase may gain between 5 to 10 pounds or more.
The Role of GLP-1 Medications
To address menopause-related weight gain, some women are turning to glucagon-like peptide-1 (GLP-1) receptor agonist medications, such as Wegovy and Zepbound. Data reveals that women aged 50 to 64 in the United States are the most frequent users of these medications.
New Research Findings
A recent study published in the journal The Lancet Obstetrics, Gynaecology, & Women’s Health suggests that combining menopausal hormone therapy with tirzepatide, the active ingredient in Zepbound, may enhance weight loss for postmenopausal women. This combination therapy could provide a more effective strategy for managing weight during and after menopause.